Cannabis Science (CBIS) Acknowledges Dr. Sanjay Gupta, CNN Chief Medical Correspondent, for Objectively Addressing Treatment Benefits of Cannabis for Several Critical Ailments in Tonight's CNN Special: 'Weed 2'

CNN Chief Medical Correspondent, Dr. Sanjay Gupta, 'Doubles Down' on His Support of Medical Cannabis

Mar 11, 2014, 07:47 ET from Cannabis Science, Inc.

COLORADO SPRINGS, Colo., March 11, 2014 /PRNewswire/ -- Cannabis Science, Inc., (NASDAQ OTCQB: CBIS) a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds CNN's Dr. Sanjay Gupta for continuing to bring to public attention the medical value of cannabis to patients and the challenges that patients face in seeking cannabis-based life-savings treatments.

Leading up to the airing of his new documentary, 'Weed 2', to be aired this evening on CNN at 10 p.m. EDT, Dr. Gupta published an article in which he states, among other things, that "I am more convinced than ever that it is irresponsible to not provide the best [medical] care we can, care that often may involve marijuana.  I am not backing down on medical marijuana; I am doubling down."

You may read the full pre-documentary article at the following link:

"Dr. Gupta's well researched support for patient access to medical cannabis provides a critical voice for those in need of all effective treatment options.  The majority of Americans now shares this view.  We hope and believe that such life-saving access will continue to expand to more and more people in need," said Chad S. Johnson, Esq., Director, COO, & General Counsel of Cannabis Science Inc.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
Tel: 1.888.777.0658

Investment Inquiries:
Robert Kane, CFO & Director
Tel: 1.561.420.4824

SOURCE Cannabis Science, Inc.